Introduction: Acromegaly is diagnosed on the basis of elevated IGF1 and GH levels. Management is primarily by pituitary surgery. In Senegal, the few studies of acromegaly have been based on descriptions of isolated cases. The aim was to study aspects of acromegaly through a national multicenter registry. Methodology: This was a multicenter, retrospective study conducted from January 1er 2008 to December 31 2022 in the Dakar neurosurgery departments and the endocrinology department of the Abass Ndao hospital. It focused on confirmed cases of acromegaly followed up in our respective departments. Results: 25 cases were included, with a mean age of 42.5 ± 12 years and a sex ratio of 1.5. The main circumstances of discovery were a tumor syndrome (100%), craniofacial dysmorphia (36%), diabetes mellitus (44%), arterial hypertension (40%), decreased visual acuity (68%), photophobia (68%). Gigantism was found in 52%, and the main signs of dysmorphic syndrome were prognathism (100%), protruding cheekbones (100%), thickened lips (100%), macroglossia (100%), enlarged extremities (100%), dysphonia (92%), pneumatization of the sinuses (92%), marked wrinkles (92%). Mean plasma IGF-1 level was 610.7 ± 2 ng/ml and GH 61.3 ng/ml. Hyperprolactinemia > 100 ng/ml was found in 36%. Macroadenomas were found in 80% of cases, isolated acromegaly in 75% and mixed secretion in 25%. The proportion of patients who had undergone pituitary surgery was 96%, including 30% with postoperative transient diabetes insipidus. There was one case of post-operative death, related to pulmonary embolism. Conclusion: In our practice, the diagnosis of acromegaly remains late in view of the symptoms and frequency of macroadenomas. In the absence of somatostatin analogues, surgery was the treatment of choice, despite some complications.
References
[1]
Trivellin, G., Daly, A.F., Faucz, F.R., Yuan, B., Rostomyan, L., Larco, D.O., et al. (2014) Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation. NewEnglandJournalofMedicine, 371, 2363-2374. https://doi.org/10.1056/nejmoa1408028
[2]
Holdaway, I.M. and Rajasoorya, C. (1999) Epidemiology of Acromegaly. Pituitary, 2, 29-41. https://doi.org/10.1023/a:1009965803750
[3]
Ribeiro-Oliveira Jr, A. and Barkan, A. (2012) The Changing Face of Acromegaly—Advances in Diagnosis and Treatment. NatureReviewsEndocrinology, 8, 605-611. https://doi.org/10.1038/nrendo.2012.101
[4]
Diallo, M.M., Diallo, A.M., Balde, M.C., Kake, A., Bah, N.M., Dago, K., et al. (2012) Metabolic Complications of Acromegaly: A Revealing Ketoacidosis. Diabetes&Metabolism, 38, A76. https://doi.org/10.1016/s1262-3636(12)71294-6
[5]
Demba, D., Mané, D.I., Maguette, M., Djiby, S., Mody, N.F., Assane, N.M., et al. (2023) Profile of Pituitary Adenomas in Senegal: Epidemiological, Clinical and Therapeutic Aspects about 241 Collected Cases. OpenJournalofInternalMedicine, 13, 144-154. https://doi.org/10.4236/ojim.2023.133017
[6]
Chanson, P., Salenave, S. and Kamenicky, P. (2014) Acromegaly. Handbook of Clinical Neurology, 124, 197-219.
[7]
Giustina, A., Casanueva, F.F., Cavagnini, F., Chanson, P., Clemmons, D., Frohman, L.A., et al. (2003) Diagnosis and Treatment of Acromegaly Complications. JournalofEndocrinologicalInvestigation, 26, 1242-1247. https://doi.org/10.1007/bf03349164
[8]
Chanson, P., Bertherat, J., Beckers, A., Bihan, H., Brue, T., Caron, P., et al. (2009) French Consensus on the Management of Acromegaly. Annalesd’Endocrinologie, 70, e9-e22. https://doi.org/10.1016/j.ando.2008.12.010
[9]
Melmed, S., Casanueva, F.F., Klibanski, A., Bronstein, M.D., Chanson, P., Lamberts, S.W., et al. (2012) A Consensus on the Diagnosis and Treatment of Acromegaly Complications. Pituitary, 16, 294-302. https://doi.org/10.1007/s11102-012-0420-x
[10]
Alberti, K.G.M.M., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al. (2009) Harmonizing the Metabolic Syndrome: A Joint Interim Statement of International Diabetes Feder Cart Association, World heart federation: Internation Artherosclerosis Society; and International Assocation for the Study of Odesity. Circulation, 120, 1640-1645. https://doi.org/10.1161/circulationaha.109.192644
[11]
Cole, T.J., Bellizzi, M.C., Flegal, M.E., et al. (2000) Establishing a Standard Definition for Child Overweight and Obesity Worldwide: International Survey. BMJ, 320, 1240-1240. https://doi.org/10.1136/bmj.320.7244.1240
[12]
Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., et al. (2009) Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes. DiabetesCare, 32, 193-203. https://doi.org/10.2337/dc08-9025
[13]
Maione, L. and Chanson, P. (2019) National Acromegaly Registries. BestPractice&ResearchClinicalEndocrinology&Metabolism, 33, Article 101264. https://doi.org/10.1016/j.beem.2019.02.001
[14]
Kaké, K., Diallo, A.A., Diallo, M.M., et al. (2019) Acromegaly Revealed during Difficult Stead-Ystate Diabetes. Revue Africaine de Médecine Interne, 6, 68-72.
[15]
Ntyonga-Pono, M.P. (1999) Update on Acromegaly: The First Case Reported in Gabon. Médecined’Afrique Noire, 46, 62-64.
[16]
Elbueishi, A.M., Pirie, F.J. and Motala, A.A. (2018) Characteristics and Outcome of Surgically Treated Acromegaly Patients Attending an Endocrinology Clinic at a Tertiary Referral Centre in Durban, South Africa over a Period of 10 Years. JournalofEndocrinology, MetabolismandDiabetesofSouthAfrica, 23, 64-69. https://doi.org/10.1080/16089677.2018.1450109
[17]
Famuyiwa, O.O., Bella, A.F. and Akinlade, K.S. (1990) Acromegaly in Ibadan—A Report of Six Cases. West African Journal of Medicine, 9, 232-238.
[18]
Monabeka, H.G., Bouenizabila, E., Nsakala-Kibangou, N., et al. (1999) Acromegaly: About Five Observations. MédecineAfriqueNoire, 46, 211-214.
[19]
Chibani, L., Boukhatemi, N., Ahmed, A., et al. (2020) Cardiovascular Complications of Acromegaly and Their Fate after Remission: About 90 Cases. AnnalesEndocrinologie, 81, 210-218.
[20]
Khodja, A., Fisli, N., Benmohammed, K., Nouri, N., Khansal, S. and Lezzar, E.K. (2018) Pretherapeutic Metabolic Profile of Acromegaly. Annalesd’Endocrinologie, 79, 286-287. https://doi.org/10.1016/j.ando.2018.06.273
[21]
Ntyonga-pono, M.P., Nguembet, A.C. and Agaya, C. (1999) Update on Acromegaly about the First Case Reported in Gabon. Médecined’Afrique Noire, 46, 62-64.
[22]
Mestron, A., Webb, S., Astorga, R., Benito, P., Catala, M., Gaztambide, S., et al. (2004) Epidemiology, Clinical Characteristics, Outcome, Morbidity and Mortality in Acromegaly Based on the Spanish Acromegaly Registry (Registro Espanol De Acromegalia, Rea). EuropeanJournalofEndocrinology, 151, 439-446. https://doi.org/10.1530/eje.0.1510439
[23]
Clayton, (1999) How Many Surgeons to Operate on Acromegalic Patients? ClinicalEndocrinology, 50, 557-559. https://doi.org/10.1046/j.1365-2265.1999.00711.x
[24]
Anagnostis, P., Efstathiadou, Z.A., Polyzos, S.A., Adamidou, F., Slavakis, A., Sapranidis, M., et al. (2011) Acromegaly: Presentation, Morbidity and Treatment Outcomes at a Single Centre. InternationalJournalofClinicalPractice, 65, 896-902. https://doi.org/10.1111/j.1742-1241.2011.02682.x
[25]
Abs, R., Verhelst, J., Maiter, D., Van Acker, K., Nobels, F., Coolens, J., et al. (1998) Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients. TheJournalofClinicalEndocrinology&Metabolism, 83, 374-378. https://doi.org/10.1210/jcem.83.2.4556
[26]
Freda, P.U., Katznelson, L., van der Lely, A.J., Reyes, C.M., Zhao, S. and Rabinowitz, D. (2005) Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis. TheJournalofClinicalEndocrinology&Metabolism, 90, 4465-4473. https://doi.org/10.1210/jc.2005-0260
[27]
Cozzi, R., Montini, M., Attanasio, R., Albizzi, M., Lasio, G., Lodrini, S., et al. (2006) Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage. TheJournalofClinicalEndocrinology&Metabolism, 91, 1397-1403. https://doi.org/10.1210/jc.2005-2347
[28]
Maiza, J.C., Vezzosi, D., Matta, M., Donadille, F., Loubes‐Lacroix, F., Cournot, M., et al. (2007) Long‐Term (Up to 18 Years) Effects on GH/IGF‐1 Hypersecretion and Tumour Size of Primary Somatostatin Analogue (SSTa) Therapy in Patients with GH‐Secreting Pituitary Adenoma Responsive to SSTa. ClinicalEndocrinology, 67, 282-289. https://doi.org/10.1111/j.1365-2265.2007.02878.x
[29]
van der Lely, A.J., Biller, B.M.K., Brue, T., Buchfelder, M., Ghigo, E., Gomez, R., et al. (2012) Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in Acrostudy. TheJournalofClinicalEndocrinology&Metabolism, 97, 1589-1597. https://doi.org/10.1210/jc.2011-2508
[30]
Colao, A., Pivonello, R., Auriemma, R.S., De Martino, M.C., Bidlingmaier, M., Briganti, F., et al. (2006) Efficacy of 12-Month Treatment with the GH Receptor Antagonist Pegvisomant in Patients with Acromegaly Resistant to Long-Term, High-Dose Somatostatin Analog Treatment: Effect on IGF-I Levels, Tumor Mass, Hypertension and Glucose Tolerance. EuropeanJournalofEndocrinology, 154, 467-477. https://doi.org/10.1530/eje.1.02112
[31]
Jane, J.A., Starke, R.M., Elzoghby, M.A., Reames, D.L., Payne, S.C., Thorner, M.O., et al. (2011) Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome. TheJournalofClinicalEndocrinology&Metabolism, 96, 2732-2740. https://doi.org/10.1210/jc.2011-0554
[32]
Babu, H., Ortega, A., Nuno, M., Dehghan, A., Schweitzer, A., Bonert, H.V., et al. (2017) Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. Neurosurgery, 81, 357-366. https://doi.org/10.1093/neuros/nyx020
[33]
Shah, S. and Har-El, G. (2001) Diabetes Insipidus after Pituitary Surgery: Incidence after Traditional versus Endoscopic Transsphenoidal Approaches. AmericanJournalofRhinology, 15, 377-379. https://doi.org/10.1177/194589240101500604
[34]
Zhu, X., Wang, Y., Zhao, X., Jiang, C., Zhang, Q., Jiang, W., et al. (2015) Incidence of Pituitary Apoplexy and Its Risk Factors in Chinese People: A Database Study of Patients with Pituitary Adenoma. PLOSONE, 10, e0139088. https://doi.org/10.1371/journal.pone.0139088
